| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,041 | 0,081 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | INTERVACC AB: New UK-wide strangles alert scheme launched today | 1 | Cision News | ||
| 12.11. | Intervacc AB Q3 Loss Increases | 1 | RTTNews | ||
| 12.11. | INTERVACC AB: Interim report January - September 2026 | 3 | Cision News | ||
| 03.11. | INTERVACC AB: Real-world Strangvac data shows nearly 100% protection | 2 | Cision News | ||
| 15.09. | Intervacc to present at upcoming International Healthcare Conference | 2 | Cision News | ||
| 20.08. | Intervacc AB: Interim report January - June 2026 | 207 | GlobeNewswire (Europe) | THE GROUP IN SUMMARY
THE GROUP
APRIL - JUNE
JAN - JUNE
FULL YEAR
2026
2025
2026
2025
2025
Net... ► Artikel lesen | |
| 30.07. | Intervacc AB: Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac | 300 | GlobeNewswire (Europe) | Intervacc AB (publ) today announces that it has submitted a Type II variation application to the European Medicines Agency (EMA) for Strangvac, the company's innovative vaccine against strangles in... ► Artikel lesen | |
| INTERVACC Aktie jetzt für 0€ handeln | |||||
| 29.07. | Intervacc AB: Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit | 497 | GlobeNewswire (Europe) | Intervacc AB (publ) today announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved for import into New Zealand under a Special Circumstances Permit.... ► Artikel lesen | |
| 22.05. | Intervacc AB: Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials | 239 | GlobeNewswire (Europe) | Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, has completed the evaluation of a US strain of Streptococcus equi in US horses prior to its use in a clinical trial towards... ► Artikel lesen | |
| 13.05. | Intervacc AB: Report from Annual General Meeting in Intervacc | 255 | GlobeNewswire (Europe) | Intervacc AB (publ) held its Annual General Meeting ("AGM") on Wednesday 13 May 2026, at which the following resolutions were made.
Adoption of the income statement and balance sheet
The AGM adopted... ► Artikel lesen | |
| 12.05. | Intervacc AB: Intervacc strengthens management team for future growth | 351 | GlobeNewswire (Europe) | Intervacc AB (publ), a Swedish growth company in animal health with the vaccine Strangvac registered on 16 European markets, today announces that the company is strengthening its management team through... ► Artikel lesen | |
| 12.05. | Intervacc AB: Interim report January - March 2026 | 284 | GlobeNewswire (Europe) | The Group in summary
01/01/26
01/01/25
01/01/25
-31/03/26
-31/03/25
-31/12/25
Net... ► Artikel lesen | |
| 16.04. | Intervacc AB: Unprecedented decision opens the way for the launch of Strangvac in Iceland | 277 | GlobeNewswire (Europe) | Intervacc AB (publ) announces that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland.
Strangles, a potentially lethal infection... ► Artikel lesen | |
| 19.03. | Intervacc AB: Intervacc announces breakthrough protection against Streptococcus suis infection in piglets | 335 | GlobeNewswire (Europe) | Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating... ► Artikel lesen | |
| 17.02. | Intervacc AB: Year-end report January - December 2025 | 359 | GlobeNewswire (Europe) | The Group in summary
01/10/25
01/10/24
Full year
Full year
-31/12/25
-31/12/24
2025
2024
Net... ► Artikel lesen | |
| 05.02. | Intervacc AB: Intervacc announces change of CEO | 464 | GlobeNewswire (Europe) | The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO.
Simultaneously, the Board has appointed... ► Artikel lesen | |
| 16.12.25 | Intervacc AB: Clinical studies with Strangvac have begun in the U.S. market | 294 | GlobeNewswire (Europe) | Intervacc AB (publ) announces that the company has started the first phase of clinical safety studies in horses in the United States as part of the approval process for Strangvac in the U.S.
The initial... ► Artikel lesen | |
| 19.11.25 | Intervacc AB: Interim report January - September 2025 | 288 | GlobeNewswire (Europe) | The Group in summary
01/07/25
01/07/24
01/01/25
01/01/24
Full year
-30/09/25
-30/09/24
-30/09/25
-30/09/24
2024
Net... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,395 | -0,71 % | NanoRepro nach starkem H1-Bericht: Diese Marke entscheidet jetzt | ||
| PALATIN TECHNOLOGIES | 5,150 | 0,00 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| BRAIN BIOTECH | 2,500 | +0,81 % | Brain Biotech bestätigt 9M-Zahlen: Warum der große Deal nicht reicht | ||
| AAP IMPLANTATE | 1,440 | -3,36 % | aap Implantate - Aktie vor Neubewertung? CEO und COO im Interview: "Die Basis steht, jetzt schalten wir auf Wachstum." | Eine spannende Sondersituation zeichnet sich derzeit bei der aap Implantate AG (ISIN: DE000A3H2101) ab: Nach Jahren der Restrukturierung und hohen regulatorischen Aufwendungen hat der Berliner Spezialist... ► Artikel lesen | |
| CO.DON | 0,005 | -28,57 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.10.2026 | The following instruments on XETRA do have their last trading day on 30.10.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.10.2026ISIN NameDE000A41YD32 BIOXXMED AG INH O.N.DE000HLB78G8... ► Artikel lesen | |
| CLINUVEL | 4,350 | -1,14 % | CLINUVEL PHARMACEUTICALS LIMITED: Change in substantial holding - Updated | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| BIO-GATE | 2,100 | -3,67 % | Original-Research: Bio-Gate AG (von BankM AG): Kaufen | Original-Research: Bio-Gate AG - von BankM AG
10.11.2026 / 12:44 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,150 | +3,00 % | COSCIENS Biopharma Inc. Q3 Loss Widens | ||
| EDITAS MEDICINE | 1,675 | +3,40 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| EXELIXIS | 62,81 | +0,95 % | Where Will Exelixis Be in 5 Years? 1 Experimental Drug Could Change Everything | ||
| EVONEXT | 2,460 | 0,00 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26 | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26
16-Nov-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| GERON | 0,895 | -1,52 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen |